SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from BioCardia, Inc. (BCDA) (CIK 0000925741) (BCDA) — Aug 1, 2019

BioCardia, Inc. (BCDA) (CIK 0000925741)
Date: Aug. 1, 2019 · CIK: 0000925741 · Accession: 0001437749-19-015091

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-230779

Date
July 31, 2019
Author

Form
CORRESP
Company
BioCardia, Inc. (BCDA) (CIK 0000925741)

Letter

bcda20190731_corresp.htm

July 31, 2019

Via EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549-3720

Attention: Jeffrey Gabor

Re:

BioCardia, Inc.

Registration Statement on Form S-1

Filed on July 31, 2019

File No. 333-230779

Acceleration Request

Requested Date: August 1, 2019

Requested Time: 4:30 P.M. Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, BioCardia, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-230779) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Company may request via telephone to the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”). The Company hereby authorizes Nathan Robinson of Wilson Sonsini Goodrich & Rosati, Professional Corporation, counsel for the Company, to make such request on the Company’s behalf.

The Company requests that it be notified of the effectiveness of the Registration Statement by telephone to Nathan Robinson of Wilson Sonsini Goodrich & Rosati, Professional Corporation at (512) 338-5407 or via email at nrobinson@wsgr.com. If notice of effectiveness is given by telephone, please also provide a copy of the Commission’s order declaring the Registration Statement effective to Nathan Robinson via facsimile at (512) 338-5499.

Please direct any questions or comments regarding this acceleration request to Nathan Robinson at (512) 338-5407.



Sincerely,


Show Raw Text
CORRESP
1
filename1.htm

	bcda20190731_corresp.htm

July 31, 2019

Via EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549-3720

			Attention:
			Jeffrey Gabor

			Re:

			BioCardia, Inc.

			Registration Statement on Form S-1

			Filed on July 31, 2019

			File No. 333-230779

			Acceleration Request

			Requested Date:
			August 1, 2019

			Requested Time:
			4:30 P.M. Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, BioCardia, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-230779) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Company may request via telephone to the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”). The Company hereby authorizes Nathan Robinson of Wilson Sonsini Goodrich & Rosati, Professional Corporation, counsel for the Company, to make such request on the Company’s behalf.

The Company requests that it be notified of the effectiveness of the Registration Statement by telephone to Nathan Robinson of Wilson Sonsini Goodrich & Rosati, Professional Corporation at (512) 338-5407 or via email at nrobinson@wsgr.com.  If notice of effectiveness is given by telephone, please also provide a copy of the Commission’s order declaring the Registration Statement effective to Nathan Robinson via facsimile at (512) 338-5499.

Please direct any questions or comments regarding this acceleration request to Nathan Robinson at (512) 338-5407.

			

			Sincerely,

			

			

			BIOCARDIA, INC.

			

			

			

			By:

			/s/ David McClung

			

			David McClung

			

			Chief Financial Officer

			

			cc:

			Michael Danaher, Esq.

			

			Wilson Sonsini Goodrich & Rosati, Professional Corporation